{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": true, "customPriceAlertConfidence": "HIGH", "earningsTimestamp": 1679342400, "earningsTimestampStart": 1684234740, "earningsTimestampEnd": 1685102400, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": -1.02, "epsForward": -0.17, "epsCurrentYear": -0.48, "priceEpsCurrentYear": -1.8020834, "sharesOutstanding": 42828300, "bookValue": 1.9, "fiftyDayAverage": 0.75252, "fiftyDayAverageChange": 0.112479985, "fiftyDayAverageChangePercent": 0.14947109, "twoHundredDayAverage": 0.690285, "twoHundredDayAverageChange": 0.17471498, "twoHundredDayAverageChangePercent": 0.25310558, "marketCap": 37703276, "forwardPE": -5.0882354, "priceToBook": 0.45526317, "currency": "USD", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "marketState": "PRE", "regularMarketChangePercent": -1.7045438, "regularMarketPrice": 0.865, "firstTradeDateMilliseconds": 1394202600000, "priceHint": 4, "exchange": "NCM", "shortName": "Neoleukin Therapeutics, Inc.", "longName": "Neoleukin Therapeutics, Inc.", "messageBoardId": "finmb_34924763", "regularMarketChange": -0.014999986, "regularMarketTime": 1684180805, "regularMarketDayHigh": 0.8863, "regularMarketDayRange": "0.86 - 0.8863", "regularMarketDayLow": 0.86, "regularMarketVolume": 118097, "regularMarketPreviousClose": 0.88, "bid": 0.0, "ask": 0.0, "bidSize": 12, "askSize": 13, "fullExchangeName": "NasdaqCM", "financialCurrency": "USD", "regularMarketOpen": 0.8682, "averageDailyVolume3Month": 453291, "averageDailyVolume10Day": 126010, "fiftyTwoWeekLowChange": 0.49, "fiftyTwoWeekLowChangePercent": 1.3066667, "fiftyTwoWeekRange": "0.375 - 1.341", "fiftyTwoWeekHighChange": -0.47599995, "fiftyTwoWeekHighChangePercent": -0.35495895, "fiftyTwoWeekLow": 0.375, "fiftyTwoWeekHigh": 1.341, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "3.0 - Hold", "tradeable": false, "cryptoTradeable": false, "displayName": "Neoleukin Therapeutics", "symbol": "NLTX"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "188 East Blaine Street", "address2": "Suite 450", "city": "Seattle", "state": "WA", "zip": "98102", "country": "United States", "phone": "866 245 0312", "website": "https://www.neoleukin.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.", "fullTimeEmployees": 56, "companyOfficers": [{"maxAge": 1, "name": "Ms. Donna M. Cochener-Metcalfe J.D.", "age": 47, "title": "Gen. Counsel, Interim CEO & Corp. Sec.", "yearBorn": 1975, "fiscalYear": 2022, "totalPay": {"raw": 403753, "fmt": "403.75k", "longFmt": "403,753"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. David  Baker M.D., Ph.D.", "title": "Co-Founder", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Sean Michael Smith", "age": 36, "title": "Interim Chief Financial Officer", "yearBorn": 1986, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Kamran  Alam", "age": 48, "title": "Sr. Strategic Advisor", "yearBorn": 1974, "fiscalYear": 2019, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "auditRisk": 8, "boardRisk": 2, "compensationRisk": 9, "shareHolderRightsRisk": 8, "overallRisk": 6, "governanceEpochDate": 1682899200, "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}